Recombinant mistletoe lectin (rML) is successful in treating human ovarian cancer cells transplanted into severe combined immunodeficient (SCID) mice.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Cancer Letters

• Publication date

  2000-03-31

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0304-3835(99)00387-0PMID 10704739
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Sialic Acids in Molecular and Cellular Interactions

  2008cited by this paper
• Characterization of recombinant and plant-derived mistletoe lectin and their B-chains.

  1999cited by this paper
• Expression of N-Acetyl Galactosaminylated and Sialylated Glycans by Metastases Arising from Primary Breast Cancer

  1999cited by this paper
• Cloning of the mistletoe lectin gene and characterization of the recombinant A-chain.

  1999cited by this paper
• Effects of a standardized mistletoe preparation on metastatic B16 melanoma colonization in murine lungs.

  1998cited by this paper
• Immunophenotype of human ovarian malignancies (cystadenocarcinomata and mixed müllerian tumor) established in SCID mice.

  1997cited by this paper
• Cell biological and immunopharmacological investigations on the use of mistletoe lectin I (ML-I)

  1996cited by this paper
• Biochemistry and Role of Sialic Acids

  1995cited by this paper
• Biochemical, histochemical and cell biological investigations on the actions of mistletoe lectins I, II and III with human breast cancer cell lines

  1995cited by this paper
• [Immunoactive effects of various mistletoe lectin-1 dosages in mammary carcinoma patients].

  1995cited by this paper
• Biology of the Sialic Acids

  1995cited by this paper
• Mistletoe treatment for cancer review of controlled trials in humans.

  1994cited by this paper
• Is the binding of mistletoe lectins I and III a useful prognostic indicator in colorectal carcinoma?

  1994cited by this paper
• Exploiting altered glycosylation patterns in cancer: progress and challenges in diagnosis and therapy.

  1994cited by this paper
• Evolution and pathophysiology of the human natural anti-alpha-galactosyl IgG (anti-Gal) antibody.

  1993cited by this paper
• Influence of treatment with the immunomodulatory effective dose of the beta-galactoside-specific lectin from mistletoe on tumor colonization in BALB/c-mice for two experimental model systems.

  1991cited by this paper
• Modulatory potency of the beta-galactoside-specific lectin from mistletoe extract (Iscador) on the host defense system in vivo in rabbits and patients.

  1989cited by this paper

• Mistletoe lectins: From interconnecting proteins to potential tumour inhibiting agents

  2021cites this paper
• Plant lectins in cancer therapeutics: Targeting apoptosis and autophagy-dependent cell death.

  2019cites this paper
• Apoptosis Induction by Lectin Isolated Boletopsis leucomelas in U 937 Cells from the Mushroom

  2018cites this paper
• Viscum album (L.) in experimental animal tumors: A meta-analysis

  2017cites this paper
• Biologisch basierte komplementäre Krebstherapien

  2017cites this paper
• PRO-APOPTOTIC EFFECT OF SRL ON HUMAN COLON CANCER CELL LINES

  2016cites this paper
• Lectins with Potential for Anti-Cancer Therapy

  2015cites this paper
• Expression of recombinant viscum album coloratum lectin B-chain in the silkworm expression system and evaluation of antioxidant activity

  2015cites this paper
• Plant Lectins in Therapeutic and Diagnostic Cancer Research

  2015cites this paper
• Plant lectins in cancer prevention and treatment

  2015cites this paper
• Plant lectins in cancer prevention and treatment Biljni lektini u prevenciji i liječenju raka

  2015cites this paper
• Biljni lektini u prevenciji i liječenju raka

  2015cites this paper
• Herbal Administration and Interaction of Cancer Treatment

  2013cites this paper
• The preclinical and clinical activity of aviscumine: a potential anticancer drug.

  2011cites this paper
• Safety of higher dosages of Viscum album L. in animals and humans - systematic review of immune changes and safety parameters

  2011cites this paper
• Wirkung von Mistellektin-I im Extrakt Iscador ® M 5 mg spezial auf das Wachstums- und Metastasierungsverhalten der humanen Melanomzelllinie MV3 in vivo

  2010cites this paper
• Plant lectins: potential antineoplastic drugs from bench to clinic.

  2010cites this paper
• THE ROLE OF PLANT LECTINS IN CANCER TREATMENT

  2010cites this paper
• Viscum album L. extracts in breast and gynaecological cancers: a systematic review of clinical and preclinical research

  2009cites this paper
• Tumor-associated CD75s- and iso-CD75s-gangliosides are potential targets for adjuvant therapy in pancreatic cancer

  2008cites this paper
• Phase I trial of r viscumin (INN: aviscumine) given subcutaneously in patients with advanced cancer: a study of the European Organisation for Research and Treatment of Cancer (EORTC protocol number 13001).

  2008cites this paper
• Tumor-associated CD 75 sand iso-CD 75 s-gangliosides are potential targets for adjuvant therapy in pancreatic cancer

  2008cites this paper
• Low-dose mistletoe lectin-I reduces melanoma growth and spread in a scid mouse xenograft model

  2007cites this paper
• Molecular characterization of the recombinant A-chain of a type II ribosome-inactivating protein (RIP) from Viscum album coloratum and structural basis on its ribosome-inactivating activity and the sugar-binding properties of the B-chain.

  2006cites this paper
• Suppression of growth of tumour cell lines in vitro and tumours in vivo by mistletoe lectins.

  2006cites this paper
• Isolation and characterization of an N-linked oligosaccharide that is increased in glioblastoma tissue and cell lines.

  2005cites this paper
• Tumor‐associated CD75s gangliosides and CD75s‐bearing glycoproteins with Neu5Acα2‐6Galβ1‐4GlcNAc residues are receptors for the anticancer drug rViscumin

  2005cites this paper
• Adaptation and performance of an immuno-PCR assay for the quantification of Aviscumine in patient plasma samples.

  2005cites this paper
• Weekly 24 h infusion of aviscumine (rViscumin): a phase I study in patients with solid tumours.

  2005cites this paper
• Lectins as Bioactive Plant Proteins: A Potential in Cancer Treatment

  2005cites this paper
• UNIVERSIDADE FEDERAL DE SANTA CATARINA CENTRO DE CIÊNCIAS BIOLÓGICAS PROGRAMA DE PÓS-GRADUAÇÃO EM NEUROCIÊNCIAS CARACTERIZAÇÃO DOS EFEITOS BIOLÓGICOS DAS LECTINAS DE Canavalia brasiliensis (ConBr) E DE Canavalia ensiformes (ConA) EM PREPARAÇÕES DO SISTEMA NERVOSO CENTRAL E EM CÉLULAS

  2005cites this paper
• Influence of mistletoe lectins and cytokines induced by them on cell proliferation of human melanoma cells in vitro.

  2005cites this paper
• Cytotoxicity of the novel anti-cancer drug rViscumin depends on HER-2 levels in SKOV-3 cells.

  2004cites this paper
• Phase I trial of intravenous aviscumine (rViscumin) in patients with solid tumors: a study of the European Organization for Research and Treatment of Cancer New Drug Development Group.

  2004cites this paper
• Effect of cryoprotectants on the stability and aerosol performance of nebulized aviscumine, a 57-kDa protein.

  2003cites this paper
• Recombinant mistletoe lectin induces p53-independent apoptosis in tumour cells and cooperates with ionising radiation

  2003cites this paper
• Detection of rViscumin in plasma samples by immuno-PCR.

  2003cites this paper
• Epstein-Barr Virus ( EBV )-associated Lymphoproliferative Disease in the SCID Mouse Model : Implications for the Pathogenesis of EBVpositive Lymphomas in Man

  2003cites this paper
• Effect of Excipients on the Stability and Aerosol Performance of Nebulized Aviscumine

  2003cites this paper
• The cytotoxic effect of mistletoe lectins I, II and III on sensitive and multidrug resistant human colon cancer cell lines in vitro.

  2002cites this paper
• Dietary mistletoe lectin supplementation and reduced growth of a murine non-Hodgkin lymphoma.

  2002cites this paper
• Synergism between rViscumin and cisplatin is not dependent on ERCC-1 expression.

  2002cites this paper
• Apoptosis Induction by Lectin Isolated from the Mushroom Boletopsis leucomelas in U937 Cells

  2002cites this paper
• Mistletoe extracts standardized to mistletoe lectins in oncology: review on current status of preclinical research.

  2002cites this paper
• Beeinflusst die Misteltherapie die Abwehr epithelialer Tumoren? Eine kritische immunologische Analyse

  2001cites this paper
• Investigation of charge variants of rViscumin by two‐dimensional gel electrophoresis and mass spectrometry

  2001cites this paper
• Binding of mistletoe lectins to cutaneous malignant melanoma: implications for prognosis and therapy.

  2001cites this paper
• Apoptosis induction associated with cell cycle dysregulation by rice bran agglutinin.

  2001cites this paper
• Anticancer activity of rViscumin (recombinant mistletoe lectin) in tumor colonization models with immunocompetent mice.

  2001cites this paper
• Inhibition of Tumor Growth and Metastasis by Korean Mistletoe Lectin is Associated with Apoptosis and Antiangiogenesis

  2001cites this paper
• Immunotherapy of C3H/HeJ mammary adenocarcinoma with interleukin-2, mistletoe lectin or their combination. effects on tumour growth, capillary leakage and nitric oxide (NO) production.

  2001cites this paper
• Combined cytotoxic action of Viscum album agglutinin-1 and anticancer agents against human A549 lung cancer cells.

  2001cites this paper
• [Does mistletoe therapy influence the defense against epithelial tumors? A critical immunologic analysis].

  2001cites this paper